Literature DB >> 6088406

Interaction between feline leukaemia virus subgroups in the pathogenesis of erythroid hypoplasia.

O Jarrett, M C Golder, S Toth, D E Onions, M F Stewart.   

Abstract

The interaction of feline leukaemia virus (FeLV) of subgroups A and C in the pathogenesis of erythroid hypoplasia in cats was studied. Weanling kittens infected with FeLV-A became permanently viraemic but remained haematologically normal over a period of 36 weeks. Similar kittens inoculated with FeLV-C, which produces erythroid hypoplasia when administered to newborn kittens, neither became viraemic nor developed the disease. However, weanling kittens inoculated with a mixture of FeLV-A and C became viraemic, first with FeLV-A and then additionally with FeLV-C, and the emergence of FeLV-C into the blood coincided with the advent of erythroid hypoplasia. When FeLV-C was inoculated into five older cats which had been viraemic with FeLV-A for several months previously, it appeared in the plasma of three of the cats and erythroid hypoplasia was diagnosed in two of these, 16-20 weeks after infection with FeLV-C. These results show that FeLV-A enhances the growth of FeLV-C in cats and overcomes their age-related resistance to FeLV-C. Also, the appearance of FeLV-C in the plasma of cats viraemic with FeLV-A indicates that erythroid hypoplasia will subsequently occur rapidly. These findings are relevant to the origin of FeLV-C isolates and their occurrence in nature.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088406     DOI: 10.1002/ijc.2910340222

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  A putative cell surface receptor for anemia-inducing feline leukemia virus subgroup C is a member of a transporter superfamily.

Authors:  C S Tailor; B J Willett; D Kabat
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Retrovirus-induced feline pure red cell aplasia. Hematopoietic progenitors are infected with feline leukemia virus and erythroid burst-forming cells are uniquely sensitive to heterologous complement.

Authors:  J L Abkowitz; R D Holly; C K Grant
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

3.  Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses.

Authors:  P R Donahue; E A Hoover; G A Beltz; N Riedel; V M Hirsch; J Overbaugh; J I Mullins
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Insertional polymorphisms of endogenous feline leukemia viruses.

Authors:  Alfred L Roca; William G Nash; Joan C Menninger; William J Murphy; Stephen J O'Brien
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Molecular analysis and pathogenesis of the feline aplastic anemia retrovirus, feline leukemia virus C-Sarma.

Authors:  N Riedel; E A Hoover; P W Gasper; M O Nicolson; J I Mullins
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

6.  Nucleotide sequence and distinctive characteristics of the env gene of endogenous feline leukemia provirus.

Authors:  D V Kumar; B T Berry; P Roy-Burman
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Hematopoietic target cells of anemogenic subgroup C versus nonanemogenic subgroup A feline leukemia virus.

Authors:  G A Dean; P M Groshek; J I Mullins; E A Hoover
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

8.  Interference with superinfection and with cell killing and determination of host range and growth kinetics mediated by feline leukemia virus surface glycoproteins.

Authors:  B S Kristal; T A Reinhart; E A Hoover; J I Mullins
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus.

Authors:  Y Takeuchi; R G Vile; G Simpson; B O'Hara; M K Collins; R A Weiss
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Identification of a feline leukemia virus variant that can use THTR1, FLVCR1, and FLVCR2 for infection.

Authors:  Zvi Shalev; Simon P Duffy; Karen W Adema; Rati Prasad; Naveen Hussain; Brian J Willett; Chetankumar S Tailor
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.